Wake up daily to our latest coverage of business done better, directly in your inbox.
Get your weekly dose of analysis on rising corporate activism.
The best of solutions journalism in the sustainability space, published monthly.
Select Newsletter
By signing up you agree to our privacy policy. You can opt out anytime.
Swiss pharma giant Novartis is backing a new campaign in its long-term commitment to fighting malaria.
The Power of One campaign (www.Po1.org) aims to address the treatment gap – through direct donations and existing government commitments – in view of the 300m additional treatments estimated to be needed to treat malaria patients across Africa between now and the end of 2015. The company says that every dollar donated to the campaign will buy and deliver a treatment to a child diagnosed with malaria.
The website enables the public to purchase a treatment and track the journey of a treatment. Donors will be able to see the effect of their donation on the ground, share information with their networks and recruit other donors.Novartis is supporting the campaign financially as well as donating up to three million Coartem Dispersible treatments to match antimalarials funded by the public.
Novartis is the exclusive treatment sponsor of the campaign. Additional sponsors include Alere Inc., which is providing malaria rapid diagnostic tests, 21st Century Fox, AHAlife.com, Causes.com, Time Warner, Twitter, Venmo and others.
Zambia will be the first country to receive deliveries of treatments and tests as a result of the Power of One campaign.
The pharma company’s commitment aligns with its long history in the fight against malaria; the Novartis Malaria Initiative is one of the largest access-to-medicine programs in the healthcare industry.
Picture credit: © Furtseff | Dreamstime.com
TriplePundit has published articles from over 1000 contributors. If you'd like to be a guest author, please get in touch!
